NASDAQ:MIRMMirum Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mirum Pharmaceuticals Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $25.28 +1.77 (+7.53 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$24.50Now: $25.28▼$26.5250-Day Range$18.62MA: $20.35▼$23.5152-Week Range$6.51Now: $25.28▼$28.31Volume216,157 shsAverage Volume55,509 shsMarket Capitalization$641.86 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.Read More Beat the Market (BTM) Rank™ 3.6 Analyst's Opinion Consensus RatingMirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.71, Mirum Pharmaceuticals has a potential upside of 33.4% from its current price of $25.28.Amount of Analyst CoverageMirum Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesMirum Pharmaceuticals has received 44 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMirum Pharmaceuticals has received 38 “underperform” votes. (Add your “underperform” vote.)Community SentimentMirum Pharmaceuticals has received 53.66% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mirum Pharmaceuticals and other stocks. Vote “Outperform” if you believe MIRM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MIRM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders45.50% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions73.27% of the stock of Mirum Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to decrease in the coming year, from ($3.58) to ($4.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirum Pharmaceuticals is -7.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirum Pharmaceuticals is -7.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirum Pharmaceuticals has a P/B Ratio of 4.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.6Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.65 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MIRM Previous Symbol CUSIPN/A CIKN/A Webmirumpharma.com Phone650-667-4085Debt Debt-to-Equity Ratio0.02 Current Ratio11.99 Quick Ratio11.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.67 per share Price / Book4.46Profitability EPS (Most Recent Fiscal Year)($4.58) Net Income$-52,550,000.00 Net MarginsN/A Return on Equity-53.81% Return on Assets-48.72%Miscellaneous Employees20 Outstanding Shares25,390,000Market Cap$641.86 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $25.28 +1.77 (+7.53 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MIRM News and Ratings via Email Sign-up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Mirum Pharmaceuticals (NASDAQ:MIRM) Frequently Asked Questions How has Mirum Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Mirum Pharmaceuticals' stock was trading at $11.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MIRM shares have increased by 115.5% and is now trading at $25.28. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Mirum Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mirum Pharmaceuticals. When is Mirum Pharmaceuticals' next earnings date? Mirum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Mirum Pharmaceuticals. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals (NASDAQ:MIRM) announced its earnings results on Thursday, August, 6th. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by $0.06. View Mirum Pharmaceuticals' earnings history. What price target have analysts set for MIRM? 8 equities research analysts have issued twelve-month target prices for Mirum Pharmaceuticals' shares. Their forecasts range from $18.00 to $52.00. On average, they anticipate Mirum Pharmaceuticals' stock price to reach $33.71 in the next twelve months. This suggests a possible upside of 33.4% from the stock's current price. View analysts' price targets for Mirum Pharmaceuticals. Has Mirum Pharmaceuticals been receiving favorable news coverage? Media coverage about MIRM stock has trended very negative on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mirum Pharmaceuticals earned a daily sentiment score of -3.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Mirum Pharmaceuticals. Who are some of Mirum Pharmaceuticals' key competitors? Some companies that are related to Mirum Pharmaceuticals include TG Therapeutics (TGTX), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), Prestige Consumer Healthcare (PBH), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Xencor (XNCR), I-Mab (IMAB), Corcept Therapeutics (CORT), Ironwood Pharmaceuticals (IRWD), INDIVIOR PLC/S (INVVY), Madrigal Pharmaceuticals (MDGL) and Eidos Therapeutics (EIDX). View all competitors. What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Gilead Sciences (GILD), Opko Health (OPK), Occidental Petroleum (OXY), Pfizer (PFE), Adaptimmune Therapeutics (ADAP), British American Tobacco (BTI), Crispr Therapeutics (CRSP), Exelixis (EXEL), Fate Therapeutics (FATE) and General Motors (GM). Who are Mirum Pharmaceuticals' key executives? Mirum Pharmaceuticals' management team includes the following people: Mr. Michael G. Grey, Exec. Chairman (Age 66)Mr. Christopher Peetz, Pres, CEO & Director (Age 40)Dr. Ian Clements, Sr. VP of Fin. & Communications (Age 50)Dr. Pamela Vig Ph.D., Chief Scientific Officer (Age 48)Ms. Lara Longpre MSC, MBA, Chief Devel. Officer (Age 49) When did Mirum Pharmaceuticals IPO? (MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. What is Mirum Pharmaceuticals' stock symbol? Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIRM." Who are Mirum Pharmaceuticals' major shareholders? Mirum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Virtus ETF Advisers LLC (0.08%), Trexquant Investment LP (0.07%), Chartwell Investment Partners LLC (0.07%), UBS Group AG (0.06%) and New York State Common Retirement Fund (0.01%). Company insiders that own Mirum Pharmaceuticals stock include Christopher Peetz, Edwin Jonathan Tucker, Holdings A/S Novo, Ian Clements, James E Flynn, Laurent Fischer, Pamela Vig and Patrick J Heron. View institutional ownership trends for Mirum Pharmaceuticals. Which institutional investors are selling Mirum Pharmaceuticals stock? MIRM stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View insider buying and selling activity for Mirum Pharmaceuticals. Which institutional investors are buying Mirum Pharmaceuticals stock? MIRM stock was bought by a variety of institutional investors in the last quarter, including Virtus ETF Advisers LLC, Trexquant Investment LP, Chartwell Investment Partners LLC, and New York State Common Retirement Fund. Company insiders that have bought Mirum Pharmaceuticals stock in the last two years include Christopher Peetz, Edwin Jonathan Tucker, Holdings A/S Novo, Ian Clements, James E Flynn, Laurent Fischer, Pamela Vig, and Patrick J Heron. View insider buying and selling activity for Mirum Pharmaceuticals. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Mirum Pharmaceuticals' stock price today? One share of MIRM stock can currently be purchased for approximately $25.28. How big of a company is Mirum Pharmaceuticals? Mirum Pharmaceuticals has a market capitalization of $641.86 million. The company earns $-52,550,000.00 in net income (profit) each year or ($4.58) on an earnings per share basis. Mirum Pharmaceuticals employs 20 workers across the globe. What is Mirum Pharmaceuticals' official website? The official website for Mirum Pharmaceuticals is mirumpharma.com. How can I contact Mirum Pharmaceuticals? Mirum Pharmaceuticals' mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The company can be reached via phone at 650-667-4085 or via email at [email protected] This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
